Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

June 14, 2019

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Acute Myeloid LeukemiaMyelodysplasia
Interventions
DRUG

Oral azacitidine

Oral azacitidine (CC-486) 200 mg tablet

DRUG

Matched placebo

Oral azacitidine (CC-486) matched placebo tablet

Trial Locations (20)

Unknown

The Queen Elizabeth Hospital, Birmingham

University Hospital Bristol, Bristol

Addenbrooke's Hospital, Cambridge

University Hospital of Wales, Cardiff

Queen Elizabeth University Hospital, Glasgow

St. James's University Hospital, Leeds

Leicester Royal Infirmary, Leicester

Clatterbridge Cancer Centre, Liverpool

Hammersmith Hospital, London

King's College Hospital, London

St Bartholomew's Hospital, London

The Royal Marsden Hospital, London

University College London Hospitals, London

Manchester Royal Infirmary, Manchester

The Christie Hospital, Manchester

Freeman Hospital, Newcastle

Nottingham City Hospital, Nottingham

Churchill Hospital, Oxford

Derriford Hospital, Plymouth

Royal Hallamshire Hospital, Sheffield

All Listed Sponsors
lead

University of Birmingham

OTHER

NCT04173533 - Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT | Biotech Hunter | Biotech Hunter